LakeShore Biopharma Co., Ltd. Balance Sheet

Ask AI

Financial Statements

In millions of CNY, except per-share amounts

	Q4 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Mar 31, 2023
Current assets
Cash
Restricted cash
Accounts receivable
Advance to suppliers, net
Advance to suppliers
Inventories
Prepaid expenses and other current assets
Total current assets
Non-current assets
Property, plant and equipment
Operating lease right-of-use assets
Deferred tax assets
Intangible assets
Other non-current assets
Total non-current assets
Total assets
Current liabilities
Bank loans and other borrowings
Accounts payable
Accrued expenses and other liabilities
Operating lease liabilities
Deferred government grants - current
Deferred government grants
Total current liabilities
Non-current liabilities
Bank loans and other borrowings
Operating lease liabilities
Deferred government grants - non-current
Deferred government grants
Warrants liability
Total non-current liabilities
Total liabilities
Shareholders’equity
Ordinary shares, par value US$0.0002 per share; 250,000,000 shares authorized; 19,022,795 and 20,766,531 shares issued and outstanding as of March 31, 2024 and 2025, respectively *
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive loss
Total shareholders’ equity
Total liabilities and shareholders’ equity

Comments